Literature DB >> 8880817

Cisatracurium during halothane and balanced anaesthesia in children.

O A Meretoja1, T Taivainen, K Wirtavuori.   

Abstract

Cisatracurium, 51W89, is one of the ten stereoisomers of Tracrium which, unlike atracurium, has been reported to have a lack of histamine mediated cardiovascular effects at doses as high as 8 x ED95 in adults. We compared the time-course of neuromuscular effects of 80 micrograms.kg-1 or 100 micrograms.kg-1 cisatracurium during N2O-O2-halothane or N2O-O2-opioid anaesthesia, respectively, in 32 children 2-12 years old. Neuromuscular function was monitored by evoked adductor pollicis EMG. Even-numbered patients (n = 16) were allowed to obtain full spontaneous recovery of neuromuscular function and odd-numbered patients (n = 16) received neostigmine 45 micrograms.kg-1 together with glycopyrrolate at the time of 25% EMG recovery. Data are expressed as median with 10th to 90th percentile range. Cisatracurium had an onset time (time from administration to maximal effect) of 2.2 (1.7-3.8) or 2.3 (1.8-4.9) min, a clinical duration (time to 25% EMG recovery) of 34 (22-40) or 27 (24-33) min, and a spontaneous 25-75% recovery time (time from 25 to 75% EMG recovery) of 11 (9-13) or 11 (7-12) min during halothane or balanced anaesthesia, respectively (NS). Train-of-four ratio recovered to 0.70 in 2.5 (1.8-3.0) or 3.2 (2.1-4.3) min following neostigmine during halothane or balanced anaesthesia, respectively (NS). Changes in blood pressure or heart rate following cisatracurium were negligible. We regard cisatracurium as a safe and promising intermediate duration muscle relaxant the effects of which can easily be reversed with neostigmine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880817     DOI: 10.1046/j.1460-9592.1996.d01-8.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  4 in total

Review 1.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Randomised controlled trial comparing cisatracurium and vecuronium infusions in a paediatric intensive care unit.

Authors:  Margarita Burmester; Quen Mok
Journal:  Intensive Care Med       Date:  2005-04-07       Impact factor: 17.440

Review 3.  Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

Authors:  H M Bryson; D Faulds
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of cisatracurium besilate.

Authors:  D F Kisor; V D Schmith
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.